Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Eisai Co Ltd
Recent news which mentions Eisai Co Ltd
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
January 15, 2025
Tags
Science
Biotechnology
Biotech and Pharmaceuticals
From
CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024
Tags
Biotech and Pharmaceuticals
Biotechnology
Pharmaceuticals
From
CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags
5 Things to Know
Biogen Inc
Economy
From
CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags
Alzheimer's disease
Breaking news
Health care industry
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Business
Eisai Co Ltd
US: News
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
Business News
Companies
Novo Nordisk A/S
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
Health care industry
Business
US: News
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
Biogen Inc
Stock Picks
Business News
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Health & Science
Pharmaceuticals
Biogen Inc
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Health care industry
Eli Lilly and Co
US: News
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Healthy Returns
Health care industry
Biotech and Pharmaceuticals
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Earnings
Business
Eisai Co Ltd
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Science
Biotech and Pharmaceuticals
Biotechnology
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Business News
Pfizer Inc
Companies
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Sanofi SA
Health care industry
Business
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Business
US: News
Eisai Co Ltd
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Business News
Tesla Inc
Technology
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Eli Lilly and Co
Business
US: News
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Business News
U/S/ Economy
Biotech and Pharmaceuticals
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
US: News
Eisai Co Ltd
Social issues
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
Markets
stocks
DraftKings Inc
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Biotech and Pharmaceuticals
Science
Social issues
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Business News
Biotech and Pharmaceuticals
Policy
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
US: News
Eisai Co Ltd
Business
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
Business News
U/S/ Economy
US Economy
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Alzheimer's disease
Health care industry
Business
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Eisai Co Ltd
US: News
Business
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
World News
CVS Health Corp
Eli Lilly and Co
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
Politics
Social issues
Business
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
Companies
Business News
Biotech and Pharmaceuticals
From
CNBC.com News
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
